Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to $15.1 million.

  • Immunocore Holdings' Change in Accured Expenses fell 43.32% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.7 million, marking a year-over-year decrease of 58.63%. This contributed to the annual value of $71.5 million for FY2024, which is 82.93% up from last year.
  • According to the latest figures from Q3 2025, Immunocore Holdings' Change in Accured Expenses is $15.1 million, which was down 55.13% from $33.7 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Change in Accured Expenses ranged from a high of $33.7 million in Q2 2025 and a low of -$10.9 million during Q1 2025.
  • Moreover, its 3-year median value for Change in Accured Expenses was $15.1 million (2025), whereas its average is $13.5 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first spiked by 318.81% in 2024, then crashed by 157.09% in 2025.
  • Quarterly analysis of 3 years shows Immunocore Holdings' Change in Accured Expenses stood at $16.0 million in 2023, then crashed by 107.67% to -$1.2 million in 2024, then slumped by 43.32% to $15.1 million in 2025.
  • Its last three reported values are $15.1 million in Q3 2025, $33.7 million for Q2 2025, and -$10.9 million during Q1 2025.